In a wide-ranging interview, incoming director general of the Danish Medicines Agency Lars Bo Nielsen discusses the challenges that personalised medicine presents to regulators, building a stronger international presence for the Agency, and better leveraging the country’s world-class data infrastructure while respecting the EU’s data protection regulation.
Within Europe, we need a critical mass of experts who can follow the evolution of modern medicine and maximise the potential of personalised medicine, looking at evidence to ensure that medicines meet what is promised
